期刊文献+

补体裂解产物C5a的研究进展 被引量:6

Progress in complement cleavage product C5a
下载PDF
导出
摘要 C5a由C5裂解而来,由74个氨基酸构成,是一种潜在的前炎症因子。C5a在羧肽酶的作用下迅速变成C5adesArg,通过G蛋白受体经典的通路与C5aR结合后在天然免疫中和适应性免疫中均发挥着重要的作用,非G蛋白受体通路目前的研究还不明朗。研究发现,C5a是许多自身免疫性疾病的重要病原起始物,所以抑制C5a的释放在未来的治疗中是一个很好的策略和方向。 The 74 amino acids glycoprotein,complement component 5a(C5a),is a potent pro-inflammatory mediator cleaved enzyma tically from its precursor,C5,upon activation of the complement cascade.C5a is quickly metabolized by carboxypeptidases,forming the less potent C5adesArg.Acting via a classical G protein-coupled receptor pathway,C5a could combine with C5aR and plavs an important role both in natural immunity and adaptive immunity.While C5a's actions at the more recently discovered non-G protein-coupled receptor remain unclear.The study shows that C5a is the important pathogen,so making C5a inhibition an attractive therapeutic strategy.
出处 《免疫学杂志》 CAS CSCD 北大核心 2010年第4期362-365,共4页 Immunological Journal
关键词 补体 C5A C5AR 活化 Complement C5a C5aR Activation
  • 相关文献

参考文献24

  • 1Kohl J. Self, non-self, and danger: a complementary view [J]. Adv Exp Med Biol, 2006, 586:71-94.
  • 2Wetsel RA, Lemons RS, Le Beau MM, et al. Molecular ana lysis of human complement component C5: localization of the structural gene to chromosome 9 [J]. Biochemistry, 1988, 27(5): 1474-1482.
  • 3Monk PN, Scola AM, Madala P, et al. Function, structure and therapeutic potential of complement CSa receptors [J]. Br J Pharmaeol, 2007, 152(4): 429-48.
  • 4Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4^+ cells [J]. Immunity, 2008, 28 (3): 425-435.
  • 5Amara U, Rittirsch D, Flied M, et al. Interaction between the coagulation and complement system [J]. Adv Exp Med Biol, 2008, 632: 71-79.
  • 6Guo RF, Ward PA. Role of C5a in inflammatory responses[J]. Annu Rev Immunol, 2005, 23: 821-852.
  • 7Gavrilyuk V, Kalinin S, Hilbush BS, et al. Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties[J]. J Neurochem, 2005, 92 (5): 1140-1149.
  • 8Kalant D, Maclaren R, Cui W, et al. C5L2 is functional receptor for acylation stimulating protein[J]. J Biol Chem, 2005, 280 (25): 23936-23944.
  • 9Gao H, NeffTA, Guo RF, et al. Evidence for a functional role of the second C5a receptor C5L2 [J]. FASEB J, 2005, 19(8): 1003-1005.
  • 10Chen N J, Mirtsos C, Suh D, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a [J]. Nature, 2007, 446 (7132): 203-207.

二级参考文献15

  • 1Dempsey PW, Allison ME, Akkaraju S, et d. C3d of complement as a molecular adjuvant: bridging innate and acquiredirmnunity[J]. Science, 1996 ,271(5 247): 348- 350.
  • 2Fischer MB, Goerg S , Shen LM, et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival [J]. Science, 1998, 280(5 363) :582- 585.
  • 3Nagar B, Jones RG, Russell J, et al. X-ray crystal structure of C3d: A C3 fragment and hgand for complement receptor 2[J]. Science, 1998,280(5 367):1 277-1280.
  • 4Szakonyi G, Guthridge JM, Li D, et al. Structure of comple-ment receptor 2 in complex with Its C3d hgand[J]. Science ,2001 , 292(5 522): 1725- 1 728.
  • 5Ross TM, Xu Y, Green TD, et al. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope:DNA vaccination with gpl20-C3d fusion proteins [ J]. AIDS Res Hum Retroviruses, 2001,17(9) :829 - 835.
  • 6Ross TM, Xu Y, Bright RA, et al. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenz avirus challenge[J]. Nat Immunol , 2000 , 1(2) : 102 - 103.
  • 7Kopf M, Abel B, Gallimore A, et el. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection [ J ]. Nat Med, 2002, 8 (4) : 373 - 378.
  • 8Stager S, Alexander J, Kirby AC, et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8( + ) T-cell responses[J]. Nat Med, 2003, 9(10): 1 298- 1 292.
  • 9Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection [J]. Nat Med, 2002, 8(6): 582-587.
  • 10Sohn JH, Bora PS, Suk H J, et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells [J]. Nat Med, 2003, 9(2): 206-212.

共引文献8

同被引文献96

  • 1胡厚祥,李保胜,刘利,陈彩宇,吕凤林.过敏毒素C5a通过Calpain途径致VEC凋亡损伤[J].免疫学杂志,2009,25(4):424-427. 被引量:3
  • 2何智,陈政良.补体系统丝氨酸蛋白酶的结构与功能[J].国外医学(免疫学分册),2004,27(6):316-319. 被引量:10
  • 3张晓玲,于长隆,毛泽斌,傅欣,张继英.骨性关节炎的联合基因治疗研究[J].中国运动医学杂志,2006,25(1):5-8. 被引量:13
  • 4Argyriou AA. Molecularly targeted therapies for dysimmune neuropathies[J].Mol Med, 2009, 15(7/8):283-287.
  • 5Brannagan TH 3rd. Current treatments of chronic immune-mediated demyelinating polyneuropathies [J].Muscle Nerve, 2009, 39(5):563-578.
  • 6Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy [J]. Neurology, 2006,66( 5 ):742-744.
  • 7Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-mag polyneuropathy [J]. Neurology, 2008, 71(21):1742-1744.
  • 8Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy[J].Ann Neurol, 2009, 65(3):286-293.
  • 9Dalakas MC. Inhibition of B cell functions: implications for neurology[J]. Neurology, 2008, 70(23 ):2252-2260.
  • 10Pestronk A, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry [J]. J Neurol Neurosurg Psychiatry, 2003, 74 (4): 485-489.

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部